The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
Aditya BardiaIngrid MayerEric WinerHannah M LindenCynthia X MaBarbara A ParkerMeritxell BelletCarlos L ArteagaSravanthi CheetiMary GatesChing-Wei ChangJill FredricksonJill M SpoerkeHeather M MooreJennifer GiltnaneLori S FriedmanEdna Chow ManevalIris ChanKomal JhaveriPublished in: Breast cancer research and treatment (2022)
GDC-0810 was safe and tolerable with preliminary anti-tumor activity in heavily pretreated patients with ER + advanced/MBC, with/without ESR1 mutations, highlighting the potential for oral SERDs. Clinical Trial and registration date April 4, 2013. NCT01823835 .